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SIGNIFICANCE
There is a need for guidance on the management of ocular 
manifestations of atopic dermatitis and ocular manifesta-
tions associated with dupilumab in the Nordic region (Den-
mark, Finland, Norway and Sweden). Nordic dermatologists 
and ophthalmologists worked together to identify consen-
sus in this area, using a modified Delphi process, which 
involved voting on the extent to which the audience agreed 
with a series of statements. Consensus was reached for 22 
of the 24 statements regarding the diagnosis, treatment 
and referral of these patients, which we hope will improve 
patient management in the Nordic region.
There is a need for unified guidance on the manage-
ment of ocular manifestations of atopic dermatitis 
and ocular manifestations associated with dupilumab 
in the Nordic region (Denmark, Finland, Norway and 
Sweden). This initiative gathered Nordic dermatolo-
gists and ophthalmologists to identify consensus in 
this area using a modified Delphi process. The initia-
tive was led by a Nordic expert panel who developed 
a questionnaire that was circulated to a wider group. 
The results informed an agenda consisting of 24 state-
ments to be voted on using a 5-point Likert scale at a 
meeting in Copenhagen on 24 April 2019. A facilitator 
moderated discussion and revised statements accor-
ding to expert feedback for a second vote when re-
quired to reach consensus. Consensus was reached for 
23 statements regarding the diagnosis, treatment and 
referral of these patients, which we hope will improve 
patient management in the Nordic region.
Key words: atopic dermatitis; consensus; modified Delphi pro-
cess; ocular manifestation.
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Atopic dermatitis (AD) is a chronic skin disease with pronounced type 2 inflammation that affects 
approximately 3–5% of adults and up to 20% of child-
ren worldwide (1–5). AD is associated with a broad 
spectrum of clinical presentations and severities, which 
may be influenced by a number of factors, such as age, 
environment and genetic predisposition (5); common 
co-morbidities include allergic rhinitis and asthma (6, 
7). AD is also associated with ocular manifestations, of 
which there is currently limited awareness (8). 
The anti-interleukin-4 receptor alpha monoclonal 
antibody dupilumab (9) has been approved in the USA 
(10) and Europe (11) for the treatment of AD in patients 
whose disease has not been adequately controlled with 
prior treatments or when other therapies are not advis-
able. However, in patients with AD enrolled in 2 phase 
3 studies, dupilumab was associated with increased risk 
of conjunctivitis compared with placebo (dupilumab 300 
mg every other week (4%); dupilumab 300 mg every 
week (4%); placebo (1%)) (7). Frequent occurrence of 
conjunctivitis and blepharitis has also been reported in 
real-world use of dupilumab (12–15). It has been 
documented that the occurrence of dupilumab-associated 
ocular manifestations increases with severity of AD and 
is more common in individuals with a history of con-
junctivitis (16–18). Symptoms commonly experienced 
by patients with AD receiving dupilumab include con-
junctival redness, hyperaemia, blepharitis, dryness and 
discharge (19). The prominent features of dupilumab-as-
sociated conjunctivitis are the predominant involvement 
of the conjunctiva and hyperaemia of the limbus (18).
The pathogenesis of dupilumab-associated conjunc-
tivitis is not yet fully understood, but is associated with a 
focal scarcity of intraepithelial goblet cells, which differs 
from the histopathology of allergic conjunctivitis (20, 
21). Dupilumab-associated conjunctivitis is thought to 
be specific to patients with AD, as it is rarely experienced 
by patients receiving dupilumab for the treatment of 
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asthma or nasal polyposis (20, 22). With the advent of 
new treatments, greater scrutiny of patients with AD and 
increased observation of the ocular events associated 
with dupilumab are warranted (7, 23). 
Dermatologists have neither the facilities nor training 
in ophthalmic investigation to effectively diagnose ocular 
events and it is not a usual part of their patient workup; 
a view broadly consistent with that of the International 
Eczema Council (24). To ensure safe and optimum patient 
management, dermatologists need to understand how to 
recognize the signs and symptoms of the ocular manifesta-
tions of AD and those that may be caused by treatment, 
how to treat, and when to refer patients to an ophthalmo-
logist. As such, Sanofi Genzyme invited dermatologists 
and ophthalmologists from the Nordic region (Denmark, 
Finland, Norway and Sweden) to gather for a consensus 
meeting using a modified Delphi process to discuss the 
management of the ocular manifestations of AD, led by 
an expert group of dermatologists and ophthalmologists.
METHODS
Expert panel and other meeting attendees
The expert panel, chosen and invited by Sanofi Genzyme, consisted 
of 3 dermatologists (Maria Bradley (Sweden), Anita Remitz (Fin-
land) and Jacob P. Thyssen (Denmark)) and 2 ophthalmologists 
(Steffen Heegaard (Denmark) and Lena Ivert (Sweden)) with a 
particular interest in the management of patients with AD and re-
levant experience of the ocular events associated with dupilumab.
In addition to the expert panel, 12 dermatologists (3 each from 
Denmark, Finland, Norway and Sweden) and 1 ophthalmologist 
(from Norway) attended the meeting as advisors, all of whom 
had an interest in the management of patients with AD. Marjolein 
de Bruin-Weller, an expert dermatologist from The Netherlands, 
also participated in the meeting by providing a presentation on 
the management of ocular events associated with dupilumab (18). 
Individuals from Sanofi Genzyme were present during the meeting, 
but did not provide input on the discussions.
Modified Delphi process
The Delphi process is a recognized facilitation technique used 
to gain consensus between specialists in a particular field where 
expert opinion is important in shaping judgements (Fig. 1) (25). 
This approach provides experts with an opportunity to alter their 
response based on their peers’ opinions, thus increasing the like-
lihood of the convergence of opinions. The expert group led the 
initiative by defining the scope of the issues to be addressed; this 
was informed by a pre-meeting questionnaire that was developed 
by the expert panel and distributed to all the meeting participants 
(this comprised 29 questions and was completed between 22 March 
2019 and 1 April 2019). From this pre-meeting feedback, the expert 
group, in collaboration with the Delphi facilitator (Keena McKillen 
on behalf of OPEN Health Medical Communications), defined the 
meeting agenda and drafted 24 statements to be voted on at the 
meeting. The meeting took place on 24 April 2019.
Voting to reach consensus
During the meeting, all Nordic experts voted on a series of state-
ments about the management of the ocular manifestations of AD, 
moderated by an experienced Delphi facilitator and the possible 
answers scored on a 5-point Likert scale; in each instance, the ex-
perts could select only one answer. During the meeting, responses 
were captured using audience-response voting systems (provided 
by Crystal Interactive, Godalming, UK); this methodology pro-
vided anonymous answers and allowed the voting to be stratified 
by country of origin and specialty. All responses were reviewed 
and discussed regardless of the level of consensus obtained. If a 
consensus was not reached, experts participated in a detailed fa-
cilitated discussion to identify reasons for the lack of agreement. 
When warranted, the Delphi facilitator revised the statements 
according to the expert feedback and re-voting then occurred 
(for a maximum of 2 votes). A consensus threshold of 75% was 
pre-specified, consistent with recent consensus initiatives (26).
RESULTS
Atopic dermatitis and the eye: a guide for dermatologists
It was agreed that dermatologists should be aware of 
several ocular manifestations, including allergic conjunc-
tivitis, blepharitis, eyelid eczema, keratoconjunctivitis, 
ocular surface infections, glaucoma and cataract secondary 
to corticosteroid treatment and keratoconus, although 
it was noted by the ophthalmologists that keratoconus 
is rare in patients with AD in the Nordic region (Table 
I). The ophthalmologists also advised caution when 
diagnos ing conditions that have other possible diagno-
ses, such as rosacea for red eyes and allergic contact 
dermatitis for eyelid and periorbital eczema. Both the 
dermatologists and ophthalmologists agreed on the im-
portance of dermatologists asking their patients with AD 
whether they have any eye complaints, because patients 
may not freely volunteer information about their eyes in 
response to general health questions, as they may think 
dermatologists are only concerned with skin complaints. 
When asking patients about conditions such as rhino-
conjunctivitis, the importance of using patient-friendly 
terms, such as “hay fever”, was mentioned.
Expert group defined the scope and issues to  
be addressed based on the results of the  
pre-meeting questionnaire.
Pre-meeting questionnaire comprising  
29 questions about the ocular manifestations  
of AD circulated to all meeting attendees.
Completed between 22/03/2019 and 01/04/2019. 
Expert group, in collaboration with the  
Delphi facilitator, defined the meeting agenda  
and drafted 24 statements to be voted on at  
the meeting.
Meeting attendees vote on 
statements (up to twice). 
Answers scored on a 5-point  
Likert scale.
Meeting attendees discuss each statement  
and revise them as appropriate.
75% consensus threshold met.
75% consensus threshold not met.
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It was noted that dermatologists should be aware of 
the ocular signs and symptoms of AD and know when to 
refer patients to an ophthalmologist. The “red flag” ocular 
signs and symptoms for which dermatologists should be 
vigilant are presented in Table II. In symptomatic pa-
tients, it was agreed that dermatologists should conduct 
clinical examinations for conjunctival redness (Fig. 2a, 
b), eyelid eczema and signs of blepharitis. 
The meeting attendees agreed that it would be appro-
priate for dermatologists to treat mild allergic conjunc-
tivitis, blepharitis and eyelid eczema, but the participa-
ting ophthalmologists recommended that patients with 
more severe allergic conjunctivitis are referred to an 
ophthalmologist (Fig. 2). The ophthalmologists also 
noted that dermatologists should describe the following 
ocular signs and symptoms to patients so they can iden-
tify them and seek medical help as needed: blepharitis, 
conjunctivitis, discomfort, dry eyes, eye itching, pain, 
photophobia, redness, reduced visual acuity and tearing.
Management of ocular manifestations of atopic 
dermatitis in the dermatology clinic
The participating ophthalmologists reassured the derma-
tologists that the risk of increased intraocular pressure in 
patients using corticosteroid eye ointment on the eyelid is 
low (27), except in those patients who are corticosteroid 
sensitive. Moreover, dermatologists expressed concern 
about the long-term use of corticosteroid eye drops that 
necessitate close follow-up, which is often difficult in 
busy university hospitals. The ophthalmologists recom-
mended a very conservative approach, which was to 
consider treating conjunctivitis with low-potency topical 
corticosteroids, such as hydrocortisone sodium phosphate 
(3.35 mg/ml eye drops, up to 3 times daily for 2 weeks) 
(except in patients with glaucoma, a history of previous 
corticosteroid-induced intraocular pressure elevation 
or a history of clinically relevant viral infections) and 
frequent use of preservative-free lubricating eye drops. 
The ophthalmologists then recommended that if patients 
still required treatment for conjunctivitis after 2 weeks 
of corticosteroid treatment that they should be referred 
to an ophthalmologist (Table III). 
It was recommended that dermatologists refer patients 
with moderate-to-severe blepharitis to an ophthalmolo-
gist. Whilst the patient is waiting for their consultation 
Table I. Atopic dermatitis (AD) and the eye: a guide for dermatologists
Recommendation Level of consensus
Dermatologists should be aware of the following ocular conditions that are associated with AD:
• allergic conjunctivitis 
• blepharitis (margin of the eyelid)
• eyelid eczema (whole eyelid)
• keratoconjunctivitis
• keratoconus
• ocular surface infections, which can be bacterial or viral
• glaucoma and cataract secondary to steroid treatment
Agreed: 100% (vote 1)
In all patients, ask about any eye complaints. Agreed: 100% (vote 1)
Dermatologists should be aware of signs and symptoms, such as redness, dry eyes, tearing, photophobia, itch, pain, discomfort or reduced 
visual acuity.
Agreed: 100% (vote 2)
In all patients, ask about their history of allergic (rhino)conjunctivitis. Agreed: 94% (vote 1)
In symptomatic patients, conduct a macroscopic investigation for conjunctival redness. Agreed: 100% (vote 1)
In symptomatic patients, conduct a macroscopic investigation for eyelid eczema or signs of blepharitis. Agreed: 100% (vote 1)
Dermatologists should treat ocular manifestations of AD such as mild allergic conjunctivitis, blepharitis or eyelid eczema. Agreed: 94% (vote 2)
Refer the patient to an ophthalmologist or have the patient contact an ophthalmologist when the patient has clinical symptoms and signs of 
moderate-to-severe conjunctivitis or moderate-to-severe blepharitis.
Agreed: 100% (vote 2)
Refer the patient to an ophthalmologist or have the patient contact an ophthalmologist if mild symptoms do not abate after 2 weeks of treatment. Agreed: 100% (vote 1)
Agreed: ”strongly agree” + ”agree” votes.
Table II. Red flags (warning signs)
Signs and symptoms related to atopic dermatitis for which dermatologists 
should be vigilant
Immunodeficiency
Moderate and severe ocular redness (Fig. 2)
Ongoing viral infection with ocular involvement, such as herpes zoster or 
herpes simplex
Severe blepharitis
Worsening or persistence of eye discomfort and pain
Worsening or persistence of eye symptoms during treatment with topical 
therapies
Worsening or persistence of light sensitivity
Worsening or persistence of visual acuity
Fig. 2. Three typical patients with ocular manifestations of atopic dermatitis that should be referred to an ophthalmologist. Patient one: (a) 
moderate conjunctivitis in the right eye, and (b) a more severe conjunctivitis in the left eye. Patient two: (c) a keratoconus due to atopic dermatitis, a 
herpes simplex keratitis as well as Staphylococcus aureus keratitis prior to uveitis with secondary glaucoma. The greyness paracentrally on the cornea was 
the stromal opacification due to the deep keratitis as well as temporary vessel ingrowth and conjunctival injection. Patient three: (d) severe conjunctivitis 
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with an ophthalmologist, dermatologists should prescribe 
corticosteroid eye ointment (the combination of oxytetra-
cycline and hydrocortisone is preferred, with the addition 
of polymyxin B) to be administered up to 3 times daily for 
2 weeks (except in patients with glaucoma, a history of 
corticosteroid-induced intraocular pressure elevation or a 
history of clinically relevant viral infections). In patients 
with a history of corticosteroid-induced intraocular pres-
sure elevation or glaucoma, topical calcineurin inhibitors, 
such as cyclosporine, 1 mg/ml, eye drops, are an appro-
priate treatment for long-term dupilumab-induced atopic 
conjunctivitis. However, as topical calcineurin inhibitor 
treatment is often associated with a burning sensation that 
causes low treatment compliance, it was recommended 
that these patients can also receive oxytetracycline and 
polymyxin B without concomitant hydrocortisone. 
The ophthalmologists also noted that the barrier func-
tion of the eye surface may be affected by AD; therefore, 
in addition to prescribing topical calcineurin inhibitors 
for the treatment of periorbital eczema or eyelid eczema, 
it is appropriate to consider prescribing concomitant 
preservative-free lubricating eye drops to alleviate dis-
comfort from dry eyes. In some patients, topical calci-
neurin inhibitors have been documented to be associated 
with pain when administered on the eyelid, but not with 
increased intraocular pressure (28). Topical calcineurin 
inhibitors are used frequently as an alternative to topical 
corticosteroids to treat periorbital or eyelid eczema.
Management of ocular events associated with dupilumab
Owing to the increased risk of ocular events associated 
with dupilumab, it was noted that dermatologists should 
inform patients about the risk and/or provide patient 
information sheets that increase patient awareness of 
ocular signs and symptoms to empower them to seek 
treatment early. Both the dermatologists and ophthal-
mologists agreed that dermatologists should encourage 
patients to use lubricating eye drops 3–5 times per day, 
based on clinical judgement, even though there is no 
evidence in the literature at this time to support their 
efficacy in patients treated with dupilumab. This is wor-
thy of further evaluation. Both the dermatologists and 
ophthalmologists also agreed that dupilumab-associated 
ocular manifestations, such as prolonged/severe conjunc-
tivitis, blepharitis and redness, are the main diagnoses/
signs and symptoms that should lead to referral to an 
ophthalmologist. Dermatologists should be vigilant for 
hyperaemia of the limbus (i.e. increased redness around 
the cornea), which is common in patients with conjunc-
tivitis who are receiving dupilumab and is non-specific 
to allergic conjunctivitis.
Owing to increasing understanding of the ocular mani-
festations of AD, the participating dermatologists and 
ophthalmologists also determined that it will be essential 
to develop pragmatic, flexible cross-disciplinary patient 
management plans that can be adapted to across different 
healthcare systems.
Education of other healthcare professionals and patients
There was no consensus on whether patients with 
AD should be given specific information about which 
healthcare professional should be contacted first if they 
experience an ocular manifestation. The dermatologists 
noted that patients may contact their GP about eye com-
plaints as they are likely to be the healthcare professional 
with whom they have built the strongest relationship; 
their GP would then refer the patient to a specialist as 
appropriate. However, as many GPs are not familiar 
with dupilumab-associated conjunctivitis it could be 
misdiagnosed as rhinoconjunctivitis, which could delay 
appropriate treatment. The meeting attendees agreed 
that patients receiving dupilumab could contact their 
Table III. Management of ocular events in the dermatology clinic
Recommendation Level of consensus
Appropriate treatments for conjunctivitis include:
• lubricating eye drops
• antihistamine/mast cell stabilizers
• corticosteroid eye drops
The timescale for treatment is 2 weeks. If there is no improvement, refer to an ophthalmologist.
Agreed: 76% (vote 1)
Appropriate treatments for mild blepharitis include:
• lubricating eye drops
• antihistamine/mast cell stabilizers
• topical calcineurin inhibitors/topical corticosteroids on the eyelids
The timescale for treatment is 2 weeks. If there is no improvement, refer to an ophthalmologist.
Agreed: 94% (vote 1)
Appropriate treatments for eyelid eczema include:
• topical calcineurin inhibitors/topical corticosteroids on the eyelids
• emollient cream
Agreed: 100% (vote 1)
Consider ways of enhancing local communication between dermatologists and ophthalmologists for patients with ocular manifestations of AD or 
medication-induced ocular events.
Agreed: 100% (vote 1)
Before starting treatment with dupilumab, dermatologists should assess patients’ ocular histories. Agreed: 100% (vote 1)
Before starting treatment with dupilumab, dermatologists should inform patients of the risk of ocular manifestations associated with dupilumab. Agreed: 100% (vote 1)
Before starting treatment with dupilumab, dermatologists should inform patients of the possible benefits of the early use of preservative-free 
lubricating eye drops 3–5 times per day.
Agreed: 94% (vote 1)
Dermatologists should manage adverse events associated with dupilumab in the same way they manage the other ocular manifestations of AD. 
However, dermatologists should be extra vigilant with conjunctivitis, blepharitis and redness, and have a lower threshold for referral in patients 
exhibiting these conditions and signs.
Agreed: 82% (vote 1)
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dermatologist if they experienced an ocular manifesta-
tion, as their dermatologist was the prescribing clinician; 
alternatively, if the patient is already consulting with an 
ophthalmologist, the ophthalmologist should be the first 
point of contact (Table IV). 
As the group agreed that patients receiving dupilumab 
should be told to inform their ophthalmologist of the 
possibility of ocular manifestations, it was suggested by 
the dermatologists and ophthalmologists that a leaflet de-
tailing the possible ocular manifestations associated with 
dupilumab would be useful and should be developed and 
given to patients. A data-capture form was presented at the 
meeting that was used for the standardized examination of 
patients with dupilumab-associated ocular events during 
dupilumab clinical trials in Utrecht, The Netherlands 
and Munich, Germany (Fig. S11). The form increases 
awareness of dupilumab-associated ocular events, such 
as limbal oedema and limbitis; dermatologists provide 
the form to patients upon referral to an ophthalmologist.
Lastly, in the context of the lower occurrence of ocular 
events in patients without AD who were treated with du-
pilumab (7), the meeting attendees agreed that allergists, 
GPs, paediatricians, pharmacists and pulmonologists 
should also be educated about the ocular manifestations 
associated with AD and dupilumab treatment.
DISCUSSION
A modified Delphi process was used to achieve consensus 
owing to the absence of comprehensive and country-
specific guidance on the management of the ocular 
manifestations of AD. As the underlying mechanisms of 
the ocular manifestations of AD and the ocular events 
associated with dupilumab are only beginning to be 
understood, clinical judgement and insight are required 
to guide the clinical practice of dermatologists given the 
growing pool of scientific data.
This consensus approach was limited by the relatively 
low number of attending experts and advisors. The ex-
perts and advisors were from 4 countries in the Nordic 
region, therefore, our recommendations may not be 
applic able in other parts of the world. Clinicians in the 
region have limited experience with managing patients 
who are receiving dupilumab because it has only re-
cently been approved by the European Medicines Agency 
(EMA) for the treatment of AD. In addition, although the 
modified Delphi process is an accepted methodology, 
it is based on expert opinion and open to possible bias 
in responses. Finally, the pathogenesis of dupilumab-
associated conjunctivitis is not yet fully understood (24, 
29, 30) and we did not include discussions on potential 
exposures that could influence decisions, e.g. contact 
lenses and use of other eye drops. 
In conclusion, currently, there is an unmet need for 
unified clinical guidance on the management of the ocular 
manifestations of AD. Our consensus meeting provides 
broad recommendations on the diagnosis, treatment and 
referral of patients with ocular manifestations of AD and 
it should be used as a framework to facilitate further col-
laboration between dermatologists and ophthalmologists; 
these recommendations provide wider education to better 
support patient management in this developing area.
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